Clinical Trial Update: OSI-774 (Erlotinib, Tarceva) in Elderly Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib (OSI-774, Tarceva) in elderly patients with non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED